Qiagen Stock (NYSE:QGEN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$45.34

52W Range

$39.03 - $47.44

50D Avg

$43.28

200D Avg

$43.49

Market Cap

$9.77B

Avg Vol (3M)

$985.71K

Beta

0.40

Div Yield

$1.32 (3.00%)

QGEN Company Profile


QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

NL

Employees

5,800

IPO Date

Jun 28, 1996

Website

QGEN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Genomics / NGS$238.91M$224.80M$245.07M
PCR / Nucleic Acid Amplification$300.20M$390.80M$433.97M
Product and Service, Other$65.58M$68.11M$83.22M
Sample Technologies$662.99M$796.93M$850.64M
Diagnostic Solutions$697.63M$660.88M$638.76M

Fiscal year ends in Dec 23 | Currency in USD

QGEN Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.97B$2.14B$2.25B
Operating Income$488.95M$531.46M$630.08M
Net Income$341.30M$423.21M$512.60M
EBITDA$694.28M$824.12M$923.00M
Basic EPS$1.52$1.86$2.26
Diluted EPS$1.52$1.84$2.21

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 07, 24 | 3:58 PM
Q2 24Aug 01, 24 | 3:04 PM
Q1 24Apr 30, 24 | 12:00 AM

Peer Comparison


TickerCompany
NTRANatera, Inc.
ICLRICON Public Limited Company
ACRSAclaris Therapeutics, Inc.
GHGuardant Health, Inc.
IQVIQVIA Holdings Inc.
NEONeoGenomics, Inc.
NEOGNeogen Corporation
MEDPMedpace Holdings, Inc.
SHCSotera Health Company